PreludeDx™ Presents DCISionRT® Data in Oral Presentation at the American Society for Radiation Oncology Annual Meeting

DCISionRT® Reclassifies over 50% of DCIS Patients with Low-Risk Clinicopathology into Elevated or Residual Risk Groups Who Benefit Greatly from Radiation Therapy LAGUNA HILLS, Calif., Oct. 25, 2022 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and...

Click to view original post